Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | The use of brain stimulation as treatment for Alzheimer’s disease

Lars Wojtecki, MD, PhD, University of Düsseldorf, Düsseldorf, Germany, speaks on the use of non-invasive brain stimulation for the treatment of Alzheimer’s disease. There are many methods of non-invasively stimulating the brain, with increasing evidence showing that stimulating different areas of the brain simultaneously improves cognition. These methods include transcranial alternating current (tACS) in combination with cognitive treatment, and transcranial magnetic stimulation (TMS), which has shown to disrupt pathological networks. Gamma tACS has been observed to improve sleep level and clearance of pathological proteins in the brain. The connection between non-invasive brain stimulation and neuropathologic changes suggests that these techniques interfere with disease pathology, as well as improving symptoms. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.


Grants/Institutional Support: Hilde Ulrichs Stiftung für Parkinsonforschung, ParkinsonFonds Deutschland, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz, Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum
Honorary/Travel Grants/Consultancy: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed. Vertanical
Stock Ownership: BionTech